<DOC>
	<DOCNO>NCT02405858</DOCNO>
	<brief_summary>The purpose study evaluate percentage participant achieve prostate-specific antigen ( PSA ) response 12 week therapy baseline accord Prostate Cancer Clinical Trials Working Group ( PCWG2 ) criterion .</brief_summary>
	<brief_title>A Study Abiraterone Acetate Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly First-line Combined Androgen Blockade Therapy</brief_title>
	<detailed_description>This Phase 4 , non-randomized , multi-center ( one hospital work medical research study ) , open label ( identity study drug know participant study staff ) , single arm study abiraterone acetate investigate efficacy safety participant metastatic castration-resistant prostate cancer ( mCRPC ) fail first-line combined androgen blockade ( CAB ) therapy . The study consist Screening Phase ( 28 day prior Cycle 1 Day 1 ) , Treatment Phase ( 2 year ) , Post Treatment Phase ( 30 day last dose study drug ) . Participants receive 1000 milligram ( mg ) ( four 250 mg tablet ) abiraterone acetate orally daily . In addition , 5 mg oral prednisolone concomitantly administer twice day ( 10 mg per day ) . A 28-daily dosing cycle continue disease progression unacceptable toxicity observe . The total duration study 2 year . Participants primarily evaluate PSA response . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Participants histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell histology Participants prostatespecific antigen ( PSA ) progression define rise PSA least 1 week apart result 25 percent ( % ) increase PSA last PSA great ( &gt; ) 2 nanogram per milliliter ( ng/mL ) ( accord PCWG2 ) antiandrogen withdrawal Participants PSA progression within year start firstline CAB therapy , PSA progression without normal PSA level ( less [ &lt; ] 4.0 ng/mL ) firstline combine androgen blockade ( CAB ) therapy Participants treat cytotoxic chemotherapy ( include estramustine ) treatment prostate cancer ( neoadjuvant adjuvant chemotherapy allow last dose great equal [ &gt; = ] 1 year schedule date initial administration abiraterone acetate ) Participants target nontarget metastatic abnormality either screen bone scan , compute tomography ( CT ) magnetic resonance imaging ( MRI ) A participant know allergy , hypersensitivity , intolerance abiraterone acetate excipients A participant severe liver dysfunction ( ChildPugh Score C ) , active symptomatic viral hepatitis chronic liver disease A participant receive hormonal therapy , include dose finasteride , dutasteride , herbal product know decrease PSA level ( example : Saw Palmetto PCSPES ) within 4 week prior schedule date initial administration abiraterone acetate A participant surgery local prostatic intervention within 4 week prior schedule date initial administration abiraterone acetate A participant active infection medical condition would make prednisolone use contraindicate</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Castration-Resistant Prostate Cancer</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>ZYTIGA</keyword>
	<keyword>Prednisolone</keyword>
</DOC>